2025

Identification of favorable subgroups of childhood high-hyperdiploid acute lymphoblastic leukemia in a modern therapy era – A retrospective international study of 3,231 patients
Attarbaschi A, Enshaei A, Sonnenberg S, Arfeuille C, Barbaric D, Behrmann L, Bodmer N, Boer J, Campbell M, Cario G, Cave H, Champrezou L, Elitzur S, Escherich G, Groot-Kruseman H, Boer M, Kiss C, Lazic J, Möricke A, Muhle H, Nebral K, Pieters R, Rohrlich P, Schrappe M, Sramkova L, Vora A, Zsigrai E, Borkhardt A, Zimmermann M, Moorman A
2025.

2024

Biologic and clinical analysis of childhood gamma delta T-ALL identifies LMO2/STAG2 rearrangements as extremely high-risk
Kimura S, Park C, Montefiori L, Iacobucci I, Pölönen P, Gao Q, Arnold E, Attarbaschi A, Brown A, Escherich G, Muhle H, Inaba H, Mullighan C
CANCER DISCOV. 2024.

2022

Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial
Mezger K, Ebert S, Muhle H, Stadt U, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, Schmid I, Schramm F, Zimmermann M, Horstmann M, Escherich G
PEDIATR BLOOD CANCER. 2022;69(12):.

Letzte Aktualisierung aus dem FIS: 01.02.2026 - 05:19 Uhr